1. Home
  2. ATOS

ATOS

Atossa Therapeutics Inc.

Logo Atossa Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Founded: 2009 Country:
United States
United States
Employees: N/A City: SEATTLE
Market Cap: 171.7M IPO Year: 2012
Target Price: $4.50 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.24 EPS Growth: N/A
52 Week Low/High: $0.59 - $2.31 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: